DOCSLIB.ORG

Written Testimony of the Department of the Attorney General Thirty-First Legislature, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Written Testimony of the Department of the Attorney General Thirty-First Legislature, 2021 WRITTEN TESTIMONY OF THE DEPARTMENT OF THE ATTORNEY GENERAL THIRTY-FIRST LEGISLATURE, 2021 ON THE FOLLOWING MEASURE: S.B. NO. 738, RELATING TO SCHEDULE I SUBSTANCES. BEFORE THE: SENATE COMMITTEE ON JUDICIARY DATE: Friday, February 19, 2021 TIME: 9:30 a.m. LOCATION: State Capitol, Via Videoconference TESTIFIER WRITTEN TESTIMONY ONLY (For more information, contact Laura Maeshiro, Deputy Attorney General, at 587-2978) Chair Rhoads and Members of the Committee: The Department of the Attorney General provides the following comments. The purposes of this bill are to remove psilocybin and psilocyn from Schedule I of chapter 329, Hawaii Revised Statutes (HRS), and require the Department of Health to establish designated treatment centers for therapeutic administration of these substances. The bill also establishes a review panel to review and assess the effects of this bill. Under both Hawaiʻi and federal law, psilocybin and psilocyn are Schedule I controlled substances. See HRS § 329-14(d)(26), (27); 21 U.S.C. § 812(c)(15), (16). Possessing either of these substances, in any amount, is currently illegal under both state and federal law. See HRS §§ 712-1240, 712-1243 (possession is a Class C felony); 21 U.S.C. § 844(a) (imprisonment up to one year, and/or $1000 minimum fine for the first offense). Section 2 of the bill proposes to remove psilocybin and psilocyn as state controlled substances, which would eliminate state criminal penalties and enforcement for their manufacture, distribution, or possession. The manufacture, distribution, or possession of psilocybin and psilocin would still be illegal under federal law and subject to federal enforcement. Thank you for the opportunity to provide comments on this bill. 821030_3 DAVID Y. IGE ELIZABETH A. CHAR, M.D. GOVERNOR OF HAWAII DIRECTOR OF HEALTH STATE OF HAWAII DEPARTMENT OF HEALTH P. O. Box 3378 Honolulu, HI 96801-3378 [email protected] Testimony in OPPOSITION to SB738 RELATING TO SCHEDULE I SUBSTANCES. SENATOR KARL RHOADS, CHAIR SENATE COMMITTEE ON JUDICIARY Hearing Date: February 19, 2021 Room Number: N/A 1 Department Testimony: The Department of Health (DOH) respectfully opposes this measure 2 based on its prohibitive risk and cost, as well as inappropriate placement of a clinical research 3 program with a public health agency. 4 Although psilocybin may have benefits for persons with certain mental health disorders based on 5 several small studies, the circumstances for safe and effective administration are far from proven 6 and routine therapeutic administration by DOH creates unnecessary hazards with unknown 7 public health value. 8 DOH is a health care provider of last resort that administers eligibility-based health care 9 programs for some of Hawaii’s most vulnerable residents. Designated treatment centers for 10 specialized therapies for which the only criteria appear to be medical necessity is best left to the 11 private sector which may better balance risk, economic sustainability, security, research benefit, 12 and therapeutic value. 13 The evaluation of psilocybin treatment centers required by this measure should be considered 14 human subject research for which DOH is ill-equipped, and which is the domain of academic 15 medicine or university-level clinical trials and research. The lack of published clinical practice 16 guidelines and best practices also places this squarely in the realm of medical research. 17 Furthermore, the qualifications of the review panel proposed by this measure do not include 18 experience or credentials to rigorously evaluate study design, evidence levels, medical ethics, 19 clinical risk, and other common dimensions of a health care intervention for which randomized 20 double-blind clinical trials have not been performed. SB738 Page 2 of 2 1 Lastly, physical security is a significant and costly concern. Experience with Hawaii’s medical 2 cannabis program demonstrated that millions of dollars in startup costs were required to comply 3 with physical and financial security and human health safety concerns. This measure contains no 4 appropriation, nor identifies supply chain and logistics management issues. 5 It is worth repeating that the Department of Health does not conduct human health research and 6 clinical trials, nor is a provider of direct clinical care to the general public. The human health, 7 financial, and ethical risks to the Department of Health and State of Hawaii are significant and 8 divert resources away from traditional public health program beneficiaries. 9 Thank you for the opportunity to testify. 10 Offered Amendments: N/A. 11 DAVID Y. IGE MAX N. OTANI GOVERNOR DIRECTOR Maria C. Cook Deputy Director Administration Tommy Johnson STATE OF HAWAII Deputy Director DEPARTMENT OF PUBLIC SAFETY Corrections 919 Ala Moana Boulevard, 4th Floor Jordan Lowe Honolulu, Hawaii 96814 Deputy Director Law Enforcement No. TESTIMONY ON SENATE BILL 738 RELATING TO SCHEDULE I CONTROLLED SUBSTANCES. By Max N. Otani, Director Senate Committee on Judiciary Senator Karl Rhoads, Chair Senator Jarrett Keohokalole, Vice Chair Friday, February 19, 2021; 9:30 a.m. Via Videoconference Chair Rhoads, Vice Chair Keohokalole, and Members of the Committee: The Department of Public Safety (PSD) respectfully opposes Senate Bill (SB) 738, which would: 1) remove psilocybin and psilocyn from the list of Schedule I substances; 2) require the Department of Health (DOH) to establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn; and 3) establish a review panel to review and assess the effects of SB 738. The Department has two important concerns in opposition. First, PSD opposes SB 738 because it would create a conflict between Hawaii law and federal law, which would cause confusion in the State of Hawaii over the legality of psilocybin and psilocyn. SB 738 proposes to remove psilocybin and psilocyn from the State’s list of Schedule I controlled substances, thereby removing state controlled substances regulation over both psilocybin and psilocyn. However, under current federal law in 21 USC 812, both psilocybin and psilocyn are still listed as federal Schedule I controlled substances. Although Section 329-11, Hawaii Revised Statutes (HRS), authorizes the Legislature to reschedule controlled substances, the Supremacy Clause of the U.S. Constitution would take precedence over State law. "An Equal Opportunity Employer/Agency" Testimony on SB 738 Senate Committee on Judiciary February 19, 2021 Page 2 The Supremacy Clause of the United States Constitution states: “This Constitution and the laws of the United States which shall be made in Pursuance thereof; and all Treaties made, or which shall be made, under the Authority of the United states, shall be the supreme Law of the Land; and the Judges in every State shall be bound thereby, any Thing in the Constitution or laws of any State to the Contrary notwithstanding.” PSD notes that for SB 738 to be viable, the federal Controlled Substances statutes must first be changed. If SB 738 was to be enacted now, psilocybin and psilocyn would not be controlled in Hawaii, but would still be illegal and controlled under federal law. This would cause great confusion and disharmony between state and federal law. It could produce a scenario in which members of the community who may think that psilocybin and psilocyn are legal may be arrested and prosecuted by federal law enforcement authorities. Second, PSD opposes HB 738 because in its current construction, HB 738 reads as though the intent of the Legislature is to legalize psilocybin and psilocyn by removing it from Schedule I, while simultaneously directing the development of treatment centers and a review panel. PSD does not support the descheduling of psilocybin and psilocyn, because of the resulting inconsistency with federal law. If the intent of the Legislature is to establish psilocybin and psilocyn treatment centers, it would be preferable to follow the model of the Medical Marijuana program, which created a State of Hawaii exception from the substance’s Schedule I designation in order to allow its use for medical purposes, rather than descheduling these substances and creating conflict with federal law and causing questions and confusion concerning their legality. Thank you for the opportunity to testify on this measure. DAVID Y. IGE TESTIMONY BY: GOVERNOR JADE T. BUTAY DIRECTOR Deputy Directors LYNN A.S. ARAKI-REGAN DEREK J. CHOW ROSS M. HIGASHI EDWIN H. SNIFFEN STATE OF HAWAII DEPARTMENT OF TRANSPORTATION 869 PUNCHBOWL STREET HONOLULU, HAWAII 96813-5097 February 19, 2021 9:30 A.M. State Capitol, Videoconference S.B. 738 RELATING TO SCHEDULE I SUBSTANCES Senate Committee on Judiciary The Department of Transportation (DOT) offers comments for S.B. 738, which removes psilocybin and psilocyn from the list of Schedule I substances. DOT’s top priority is keeping Hawaii’s roadway users safe and reducing the number of serious injuries and fatalities on our roads. We have concerns regarding this bill, which appears to remove psilocybin and psilocyn entirely from the Schedule of Controlled Substances. Doing so would be problematic for impaired driving adjudication because of Hawaii’s current definition of “drug” in our Operating a Vehicle Under the Influence of an Intoxicant statute. Psilocybin and psilocyn have hallucinogenic properties that may impact driving abilities due to its effects (dizziness, blurry vision, impaired distance perception, objects appear to develop waves and wave-like patterns, etc.). DOT is primarily concerned about improving highway safety and protecting the lives of our community members and visitors. DOT coordinates specialized training and certifies law enforcement officers to recognize impairment in drivers under the influence of drugs through its Drug Recognition Expert program to combat this issue. Thank you for the opportunity to provide testimony. POLICE DEPARTMENT CITY AND COUNTY OF HONOLULU 801 SOUTH BERETANIA STREET - HONOLULU. HAWAII 96813 TELEPHONE (808) 529-3111 - INTERNET wvvw honolulupd org »' -1- ‘H :_-fl‘, ,__, "-._‘|| SUSAN BALLARD RICK BLAIIGIARDI Z; _—__' "-.'- CHIEF MAYOR J! "iv ’-'~.! TF7? JOHN D Mt:C/IRTHV -.I’ -xx.
Load more

Recommended publications
  • 4/23/2015 1 •Psychedelics Or Hallucinogens
    4/23/2015 Hallucinogens •Psychedelics or This “classic” hallucinogen column The 2 groups below are quite different produce similar effects From the classic hallucinogens Hallucinogens Drugs Stimulating 5HT Receptors Drugs BLOCKING ACH Receptors • aka “psychotomimetics” LSD Nightshade(Datura) Psilocybin Mushrooms Jimsonweed Morning Glory Seeds Atropine Dimethyltryptamine Scopolamine What do the very mixed group of hallucinogens found around the world share in common? •Drugs Resembling NE Drugs BLOCKING Glutamate Receptors •Peyote cactus Phencyclidine (PCP) •Mescaline Ketamine All contain something that resembles a •Methylated amphetamines like MDMA High dose dextromethorphan •Nutmeg neurotransmitter •New synthetic variations (“bath salts”) •5HT-Like Hallucinogens •LSD History • Serotonin • created by Albert Hofmann for Sandoz Pharmaceuticals LSD • was studying vasoconstriction produced by ergot alkaloids LSD • initial exposure was accidental absorption thru skin • so potent ED is in millionths of a gram (25-250 micrograms) & must be delivered on something else (sugar cube, gelatin square, paper) Psilocybin Activate 5HT2 receptors , especially in prefrontal cortex and limbic areas, but is not readily metabolized •Characteristics of LSD & Other “Typical” •Common Effects Hallucinogens • Sensory distortions (color, size, shape, movement), • Autonomic (mostly sympathetic) changes occur first constantly changing (relatively mild) • Vivid closed eye imagery • Sensory/perceptual changes follow • Synesthesia (crossing of senses – e.g. hearing music
    [Show full text]
  • Hallucinogens - LSD, Peyote, Psilocybin, and PCP
    Information for Behavioral Health Providers in Primary Care Hallucinogens - LSD, Peyote, Psilocybin, and PCP What are Hallucinogens? Hallucinogenic compounds found in some plants and mushrooms (or their extracts) have been used— mostly during religious rituals—for centuries. Almost all hallucinogens contain nitrogen and are classified as alkaloids. Many hallucinogens have chemical structures similar to those of natural neurotransmitters (e.g., acetylcholine-, serotonin-, or catecholamine-like). While the exact mechanisms by which hallucinogens exert their effects remain unclear, research suggests that these drugs work, at least partially, by temporarily interfering with neurotransmitter action or by binding to their receptor sites. This InfoFacts will discuss four common types of hallucinogens: LSD (d-lysergic acid diethylamide) is one of the most potent mood-changing chemicals. It was discovered in 1938 and is manufactured from lysergic acid, which is found in ergot, a fungus that grows on rye and other grains. Peyote is a small, spineless cactus in which the principal active ingredient is mescaline. This plant has been used by natives in northern Mexico and the southwestern United States as a part of religious ceremonies. Mescaline can also be produced through chemical synthesis. Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is obtained from certain types of mushrooms that are indigenous to tropical and subtropical regions of South America, Mexico, and the United States. These mushrooms typically contain less than 0.5 percent psilocybin plus trace amounts of psilocin, another hallucinogenic substance. PCP (phencyclidine) was developed in the 1950s as an intravenous anesthetic. Its use has since been discontinued due to serious adverse effects. How Are Hallucinogens Abused? The very same characteristics that led to the incorporation of hallucinogens into ritualistic or spiritual traditions have also led to their propagation as drugs of abuse.
    [Show full text]
  • Around the Corner Canadian Equity Research Emerging Companies and Industries to Watch 3 March 2020
    Around the Corner Canadian Equity Research Emerging companies and industries to watch 3 March 2020 Tania Gonsalves, CFA | Analyst | Canaccord Genuity Corp. (Canada) | [email protected] | 1.416.996.8346 Scott McFarland | Associate | Canaccord Genuity Corp. (Canada) | [email protected] | 1.416.998.7202 Around the Corner highlights what we believe are some of the most exciting Psychedelic-derived medicines and therapies emergent private companies in Canada, and/or industry themes and trends which are yet to be fully represented in the Mental health miracle or another bad trip? public markets. When most of us think of psychedelic drugs, we think of the 1960s counterculture. We We aim to offer insight into early industry think of anti-establishment, anti-war, anti-capitalist hippies, Woodstock, tie-dye, Lucy in trends, educate investors about private the Sky, peace, love and bell bottom jeans. But before psychedelics became ingrained in companies that are making a mark, and the counterculture, they were found in a lab. The first wave of scientific research on identify companies that may enter the psychedelics took place between 1950-65. Sandoz Pharmaceutics, what is now Novartis public markets in the future. AG (NVS-NYSE), the third largest pharmaceutical company in the world, used to market We do not provide any ratings or price LSD and psilocybin for psychotherapeutic purposes. Psychedelics weren’t born of the targets, nor should any be inferred, for counterculture. They were killed by it. The proliferation of recreational use spurred any uncovered company featured in government intervention and by 1971, psilocybin, LSD, ibogaine, mescaline, peyote, Around the Corner.
    [Show full text]
  • Psilocybin Mushrooms Fact Sheet
    Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses.
    [Show full text]
  • Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters
    Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant.
    [Show full text]
  • Responding to an Urgent Mental Health Crisis Challenges and Solutions for People Suffering with Treatment-Resistant Depression
    Responding to an urgent mental health crisis Challenges and solutions for people suffering with treatment-resistant depression A White Paper from COMPASS Pathways August 2021 Contents Foreword from George Goldsmith ..............................................................................................................03 Introduction ........................................................................................................................................................05 Executive summary . .........................................................................................................................................06 Part I: Treatment-resistant depression - background and challenges .................................................08 o Mental health disorders o Depression: an overview o Major depressive disorder and treatment-resistant depression o Suicide and treatment-resistant depression o Mental health care spending and use of services Part II: Current approaches and limitations for treatment of depression ...........................................15 o A fragmented and inaccessible mental health care system o Treatment approaches for depression o Psychotherapy o Drug therapy o Physical (somatic) therapies o Lack of research and development for new drug treatments Part III: Emerging solutions in treatments for depression ......................................................................24 o Emerging treatment options and the challenges of getting these to patients o Psychedelic therapies: a new frontier
    [Show full text]
  • Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms
    Dominican Scholar Physician Assistant Studies | Student Department of Physician Assistant Articles Studies 2020 Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms Sofia Beck Dominican University of California https://doi.org/10.33015/dominican.edu/2020.PAS.10 Survey: Let us know how this paper benefits you. Recommended Citation Beck, Sofia, "Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms" (2020). Physician Assistant Studies | Student Articles. 7. https://doi.org/10.33015/dominican.edu/2020.PAS.10 This Article is brought to you for free and open access by the Department of Physician Assistant Studies at Dominican Scholar. It has been accepted for inclusion in Physician Assistant Studies | Student Articles by an authorized administrator of Dominican Scholar. For more information, please contact [email protected]. ABSTRACT Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward how we treat these psychiatric disorders. Studies involving the psychedelic serotonin agonist, psilocybin, are currently experiencing a resurgence as an alternative for patients who are unresponsive to traditional treatments. Clinical trials using psilocybin in combination with psychotherapy have demonstrated sustained reductions in depression and/or anxiety symptoms. When used in medical settings, it has shown to be safe, with few side effects and no risk of dependence. However, this psychedelic compound faces many stigmas and these results have yet to be compared to current treatments or in larger populations.
    [Show full text]
  • Can Magic Mushrooms Heal Us? - the New York Times
    3/22/2021 Opinion | Can Magic Mushrooms Heal Us? - The New York Times Can Magic Mushrooms Heal Us? A very promising mental health experiment is taking shape in Oregon. By Ezra Klein Opinion Columnist March 18, 2021 Gov. Kate Brown of Oregon announced the members of the state’s newly formed Psilocybin Advisory Board this week. Why does Oregon need an official board to offer advice about the active ingredient in magic mushrooms, you ask? Because Oregon is about to become the first state in the country to try to build a support infrastructure through which psychedelic mushrooms can be woven into everyday life. This framework is different from what we’ve seen before: not legalization, not medicalization, but therapeutic use, in licensed facilities, under the guidance of professionals trained to guide psychedelic experiences. Whoa. “Like many, I was initially skeptical when I first heard of Measure 109,” Brown said in a statement. “But if we can help people suffering from PTSD, depression, trauma and addiction — including veterans, cancer patients, and others — supervised psilocybin therapy is a treatment worthy of further consideration.” [Listen to “The Ezra Klein Show,” a podcast about ideas that matter.] Measure 109, the Oregon Psilocybin Services Act, approved as a ballot measure in November, is the brainchild of Tom and Sheri Eckert, who shared a therapy practice in Portland. In 2015, the Eckerts read an article by Michael Pollan in The New Yorker titled “The Trip Treatment.” The article described the emerging research around using psychedelics as a therapeutic tool and unearthed the largely forgotten pre-Timothy Leary period in which psychedelics were widely used by psychiatrists.
    [Show full text]
  • Psychedelic Agents
    PSYCHEDELIC AGENTS: CHANGES INDUCED IN SUBJECTIVE EXPERIENCE AND BRAIN ACTIVITY Bachelor Degree Project in Cognitive Neuroscience Basic level 22.5 ECTS Spring term 2019 Louise Andersson Supervisor: Katja Valli Examiner: Joel Parthemore Abstract This thesis combines phenomenological and neuroscientific research to elucidate the effects of psychedelic agents on the human brain, mind and psychological well-being. Psychoactive plants have been used for thousands of years for ceremonial and ritual purposes. Psychedelics are psychoactive substances that affect cognitive processes and alter perception, thoughts, and mood. Illegalization of psychedelics in the 1960s rendered them impossible to study empirically but in the last couple of decades, relaxed legal restrictions regarding research purposes, renewed interest in the effects of psychedelic drugs and new brain imaging techniques have started to reveal the possibilities of these mind-altering substances. Psychedelics mainly affect the serotonin receptor 5-HT2A which in turn affects the functioning of largescale cortical areas by changing cerebral blood flow, alpha oscillations and functional connectivity. These cortical changes not only induce immediate alterations in perception and cognition but have been shown to have positive effects in therapeutic interventions for depression, anxiety, and addiction, and also positively affect well-being in general. Although the pharmacology and neurobiology of psychedelics are still poorly understood, the potential benefits justify empirical research
    [Show full text]
  • Mushroom Pioneers
    Mushroom Pioneers by John W. Allen © 2002 by John W. Allen original source: https://www.erowid.org/library/books_online/mushroom_pioneers/mushroom_pioneers2.shtml Books by John W. Allen Magic Mushrooms of the Pacific Northwest Magic Mushrooms of the Hawaiian Islands Teonanácatl: Ancient and Contemporary Shamanic Mushroom Names of Mesoamerica and Other Regions of the World Magic Mushrooms in Some Third World Countries,co-authored by Jochen Gartz, Ph.D. CD-ROMS Teonanácatl: A Bibliography of Entheogenic Mushrooms, co-authored by Jochen Gartz, Ph.D. Psilocybian Mushroom Cultivation, co-Authored by Jochen Gartz, Ph.D. Special Thanks Jonathan Ott, Larry Zoumas and Ken Thompkins soma rights re-served 1 since 23.11.2015 at http://www.en.psilosophy.info/ mushroom pioneers www.en.psilosophy.info/nhyafuitbfizbqcicpazbdjm Ethnomycological Journals Sacred Mushrooms Studies Volume V11 Copyright@ 2002 by John W. Allen Book Cover Design by John W. Allen http://mushroomjohn.com Mushroom Pioneers at MushroomJohn.com Printed in the United States Table of Contents: Information about Online Edition Dedication Endorsement Blurbs for Mushroom Pioneers Foreword Introduction The Spanish, The Aztecs and the Sacred Fungi Chapter 1. Modern Field Research on Teonanácatl 1915-1940 Chapter 2. Richard Evans Schultes Chapter 3. Rolf Singer and the Misidentification of Teonanácatl Chapter 4. The Rediscovery of Entheogenic Mushrooms Wasson's First Voyage Wasson Meets María Sabina CIA Mole James Moore - Spies on Wasson in the Search for Mind-Control Drugs Chapter 5. María Sabina Saint Mother of the Sacred Mushrooms Childhood The Coming of the Foreigners May the Force be With You Notes Chapter 6. Albert Hofmann and the Synthesis of Psilocybine and Psilocine Chapter 7.
    [Show full text]
  • Seven Controversies in Psychedelic Medicine
    Seven Controversies in Psychedelic Medicine Alex Belser, PhD Co-Investigator, Yale University Founding President, Nautilus Sanctuary Chief Clinical Officer, Adelia Therapeutics Chief Clinical Advisor, Cybin Disclosures ✧ Funding Sources, last 3 years ✧ Yale University ✧ NYU School of Medicine ✧ NYU Steinhardt School of Culture, Education, and Human Development ✧ MAPS Public Benefit Corporation ✧ Adelia Therapeutics ✧ Cybin ✧ Heffter Research Institute ✧ Synthesis Institute Psychedelic Effects Psilocybin Ketamine Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-651. Psychedelic Research: An overview 200 mushroom stones found in post-Mayan civilization in the Guatemala highlands Gold Pectorals from the Sinú culture of Columbia (1200 - 1600 c.e.) Psychedelic Clinical Trials: Count 1994-2020 (excludes ketamine) Web of science: psychedelic publication count by year Petranker, R., Anderson, T., & Farb, N. (2020). Psychedelic research and the need for transparency: Polishing Alice’s Looking Glass. Frontiers in psychology, 11, 1681. Psilocybin + Psychotherapy Interventions for Anxiety and Depression ✧ Meta analysis: large magnitude effect sizes ✧ Large pre-post and pre-follow-up effects on anxiety and depression ✧ Hedges’ gs =1.16 to 1.47 The Experimental Effects of Psilocybin on Symptoms of Anxiety and Depression: A Meta-analysis (Simon B. Goldberg, Brian T. Pace, Christopher R. Nicholas, Charles L. Raison, Paul R. Hutson,
    [Show full text]
  • A Social and Cultural History of the Federal Prohibition of Psilocybin
    A SOCIAL AND CULTURAL HISTORY OF THE FEDERAL PROHIBITION OF PSILOCYBIN A Dissertation presented to the Faculty of the Graduate School at the University of Missouri-Columbia In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy by COLIN WARK Dr. John F. Galliher, Dissertation Supervisor AUGUST 2007 The undersigned, appointed by the dean of the Graduate School, have examined the dissertation entitled A SOCIAL AND CULTURAL HISTORY OF THE FEDERAL PROHIBITION OF PSILOCYBIN presented by Colin Wark, a candidate for the degree of doctor of philosophy and hereby certify that, in their opinion, it is worthy of acceptance. Professor John F. Galliher Professor Wayne H. Brekhus Professor Jaber F. Gubrium Professor Victoria Johnson Professor Theodore Koditschek ACKNOWLEDGEMENTS The author would like to thank a group of people that includes J. Kenneth Benson, Wayne Brekhus, Deborah Cohen, John F. Galliher, Jay Gubrium, Victoria Johnson, Theodore Koditschek, Clarence Lo, Kyle Miller, Ibitola Pearce, Diane Rodgers, Paul Sturgis and Dieter Ullrich. ii TABLE OF CONTENTS ACKNOWLEDGEMENTS ................................................................................................ ii NOTE ON TERMINOLOGY ............................................................................................ iv Chapter 1. INTRODUCTION…………………………………………………………………1 2. BIOGRAPHICAL OVERVIEW OF THE LIVES OF TIMOTHY LEARY AND RICHARDALPERT…………………………………………………….……….20 3. MASS MEDIA COVERAGE OF PSILOCYBIN AS WELL AS THE LIVES OF RICHARD ALPERT AND TIMOTHY
    [Show full text]